Top Tweets for #Opthea

almost 3 years ago

$OPT.AX update. There it is - capital raise and the market dumps it to $0.45 on open (what would I know - technical analysis is astrology for men). Target around $0.41. $OPT #opthea #ASX

ElephantCapita2's tweet photo. $OPT.AX update. There it is - capital raise and the market dumps it to $0.45 on open (what would I know - technical analysis is astrology for men). Target around $0.41. $OPT #opthea #ASX https://t.co/OYt57Ezxek

ASX 🏛 The heart of Australia's financial markets

about 3 years ago

$OPT.AX - as suspected. Looks like it will fish for a double bottom. $OPT #opthea

2

6

0

1

13K

0

13

1

0

6K

@ASX

almost 3 years ago

Giri Tenneti, Senior Manager Listed Company Services at @ASX spoke to Megan Baldwin, CEO and Managing Director of @OptheaLimited. Watch the video now to learn more. https://t.co/iHmk7xafk9 #ASXListed #Video #CEO #Biotechnology #WetAMD #Opthea

ASX's tweet photo. Giri Tenneti, Senior Manager Listed Company Services at @ASX spoke to Megan Baldwin, CEO and Managing Director of @OptheaLimited.
Watch the video now to learn more.
https://t.co/iHmk7xafk9

#ASXListed #Video #CEO #Biotechnology #WetAMD #Opthea

1

2

0

3K

about 3 years ago

$OPT.AX - as suspected. Looks like it will fish for a double bottom. $OPT #opthea

over 3 years ago

$OPT.AX - not looking good here. Solid prospects, but with a while to go before the end of the trial and commercialisation, opportunity cost of holding in this tightening environment is too high. $OPT #opthea

ElephantCapita2's tweet photo. $OPT.AX - not looking good here. Solid prospects, but with a while to go before the end of the trial and commercialisation, opportunity cost of holding in this tightening environment is too high. $OPT #opthea https://t.co/tIo53vjMbE

0

4

0

1

0

2

6

0

1

13K

over 3 years ago

$OPT.AX - not looking good here. Solid prospects, but with a while to go before the end of the trial and commercialisation, opportunity cost of holding in this tightening environment is too high. $OPT #opthea

0

4

0

1

0

about 4 years ago

$OPT $OSP ASX Health Stocks: Opthea presents data at renowned conference; Osprey slashes workforce (via Stockhead) https://t.co/2bZ1Y0OVI3 #OPT #Opthea #OSP #OspreyMedicalInc #ASX #ausbiz #smallcaps #microcaps #ausstocks

0

2

0

over 4 years ago

$OPT.AX looks like it has found a base, a little shy of the measured move and gap closure. Long-term buy and hold. Short term targets $1.50-1.80, long term targets $7+. Of course, the long-term target is contingent on successful trials. #OPT #opthea $OPT

ElephantCapita2's tweet photo. $OPT.AX looks like it has found a base, a little shy of the measured move and gap closure. Long-term buy and hold. Short term targets $1.50-1.80, long term targets $7+. Of course, the long-term target is contingent on successful trials.

#OPT #opthea $OPT https://t.co/Fz2Q6gZcLp

1

2

0

Eyewire+ @eyewireplus

almost 5 years ago

#Opthea has announced FDA has granted Fast Track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with #wetAMD. https://t.co/aB5MOsTbAS

eyewireplus's tweet photo. #Opthea has announced FDA has granted Fast Track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with #wetAMD. https://t.co/aB5MOsTbAS https://t.co/FTVSDepprA

0

8

7

0

almost 5 years ago

Dual listed $OPT.AX, developing a novel therapeutic for wet AMD/DME patients. $OPT is currently undertaking ph3 trials. Plenty of time for the market to sell into uncertainty>accumulate on the cheap. Downside target ~$0.96 (refer to chart). Huge potential. #opthea #ASX #NASDAQ

ElephantCapita2's tweet photo. Dual listed $OPT.AX, developing a novel therapeutic for wet AMD/DME patients. $OPT is currently undertaking ph3 trials. Plenty of time for the market to sell into uncertainty>accumulate on the cheap. Downside target ~$0.96 (refer to chart). Huge potential.

#opthea #ASX #NASDAQ https://t.co/5CwjJLhKeJ

1

2

0

about 6 years ago

$WBA $PAR $OPT $DXB Here’s why biotech Dimerix is on a golden run (via Stockhead) https://t.co/Bpp8GsiSur #WBA #Webster #PAR #ParadigmBiopharmaceuticals #OPT #Opthea #DXB #Dimerix #ASX #ausbiz #smallcaps #microcaps #ausstocks

0

2

0

over 6 years ago

$OPT $SSG $IHL “Your Stock Request” – 5 December 2019 (via Fairmont Equities) https://t.co/aNs4sYUkpJ #OPT #Opthea #SSG #ShaverShopGroup #IHL #ImpressionHealthcare #ASX #ausbiz #smallcaps #microcaps #ausstocks

0

5

3

0

over 6 years ago

$PAR $OPT $CYP $NEU $IMM $TLX These are the 22 small cap biotechs closest to bringing a drug to market (via Stockhead) https://t.co/w3jWpdLS9Q #PAR #ParadigmBiopharmaceuticals #OPT #Opthea #CYP #CynataTherapeutics #NEU #NeurenPharmaceuticals #IMM #Immutep #TLX #TelixPharma...

1

3

1

0